Education
About Us
Working with TipRanks
Follow Us
TG Therapeutics (TGTX)
NASDAQ:TGTX
Earnings Data
Report Date
Mar 03, 2026TBA (Confirmed)
Period Ending
2025 (Q4)Consensus EPS Forecast
0.33Last Year’s EPS
0.15Same Quarter Last Year
Moderate Buy
Based on 5 Analysts Ratings
Earnings Call Summary
Earnings Call Sentiment|Positive
The earnings call highlighted strong financial performance, positive developments in clinical trials, and an increase in market presence and revenue guidance. However, there were challenges with increased operating expenses and limited ex-U.S. sales growth. Overall, the highlights significantly outweigh the lowlights.Company Guidance
Strong Financial Performance
Total revenue reached $161.7 million, an increase of 93% compared to Q3 '24 and 15% over Q2 '25. U.S. BRIUMVI net sales in Q3 totaled approximately $153 million, exceeding internal targets and Street expectations.
Positive Clinical Developments
Enrollment for the ENHANCE study completed quickly, indicating strong interest. The Phase III subcutaneous ublituximab study is on track, with potential approval and launch in 2028.
Share Repurchase Program
Completed initial $100 million share repurchase program, buying back 3.5 million shares. An additional $100 million program authorized.
Sustained Demand and Market Expansion
The CD20 class now represents nearly $10 billion in annual U.S. MS sales. BRIUMVI's market presence expanded with new prescribers and accounts.
Raised Full-Year Revenue Guidance
Full year 2025 U.S. BRIUMVI net revenue guidance increased to approximately $585 million.
TGTX Earnings History
The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.
Beat
Missed
TGTX Earnings-Related Price Changes
Report Date | Price 1 Day Before | Price 1 Day After | Percentage Change |
|---|---|---|---|
Nov 03, 2025 | $34.78 | $33.69 | -3.13% |
Aug 04, 2025 | $35.02 | $28.72 | -17.99% |
May 05, 2025 | $43.44 | $37.68 | -13.26% |
Mar 03, 2025 | $30.09 | $34.42 | +14.39% |
Earnings announcements can affect a stock’s price. This table shows the stock's price the day before and the day after recent earnings reports, including the percentage change.
FAQ
When does TG Therapeutics (TGTX) report earnings?
TG Therapeutics (TGTX) is schdueled to report earning on Mar 03, 2026, TBA (Confirmed).
What is TG Therapeutics (TGTX) earnings time?
TG Therapeutics (TGTX) earnings time is at Mar 03, 2026, TBA (Confirmed).
Where can I see when companies are reporting earnings?
You can see which companies are reporting today on our designated earnings calendar.
What companies are reporting earnings today?
You can see a list of the companies which are reporting today on TipRanks earnings calendar.
What is TGTX EPS forecast?
TGTX EPS forecast for the fiscal quarter 2025 (Q4) is 0.33.